BioCentury
ARTICLE | Product Development

KSQ sets sights on the clinic as new CEO steps in

KSQ plans to advance its first cancer program emerging from its CRISPR-based target discovery platform into the clinic this year

January 27, 2021 12:18 AM UTC

KSQ is setting a path to advance targeted oncology and immuno-oncology programs emerging from its CRISPR-based target discovery platform with the appointment of Qasim Rizvi as its new CEO and a recent deal with Takeda.

Under Rizvi, who was named CEO on Monday, KSQ Therapeutics Inc. will gear up to bring its lead candidate, a small molecule against DNA damage repair protein USP1, into the clinic this year. ...